文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

阿扎那韦/利托那韦联合拉米夫定作为病毒学抑制HIV感染者的维持治疗:一项随机试验的96周结果

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

ATLAS-M是一项96周开放标签随机非劣效试验,纳入266例接受阿扎那韦/利托那韦+2种核苷类逆转录酶抑制剂(2NRTI)且病毒学抑制的HIV感染成人,1:1换用阿扎那韦/利托那韦+拉米夫定或继续原方案。96周时双药组无治疗失败比例高于三药组,双药组病毒学失败更少,但3-4级高胆红素血症和高甘油三酯血症更常见;双药组肾功能和腰椎骨密度改善。

要点

  • 96周双药组无治疗失败103例(77.4%)高于三药组87例(65.4%),差异+12.0%(95%CI +1.2/+22.8,P=0.030)。
  • 病毒学失败双药组2例(1.5%)低于三药组9例(6.8%),未出现对研究药物的耐药。
  • 双药组3-4级高胆红素血症66.9%高于三药组50.4%(P=0.006),高甘油三酯血症6.8%高于1.5%(P=0.031),但未导致停药。

核心结论

  • 在病毒学抑制的HIV感染成人中,换用阿扎那韦/利托那韦+拉米夫定优于继续阿扎那韦/利托那韦+2NRTI,并持续改善肾功能和骨密度。

研究设计与样本

  • ATLAS-M为96周开放标签、随机、非劣效性(界值-12%)试验,纳入266例接受阿扎那韦/利托那韦+2NRTI、HIV-RNA<50拷贝/mL且CD4计数>200个细胞/mm3的HIV感染成人,1:1随机换用阿扎那韦/利托那韦+拉米夫定或继续原方案,注册号NCT01599364。

主要发现

  • 96周意向治疗人群中,双药组无治疗失败103例(77.4%)vs 三药组87例(65.4%),差异+12.0%(95%CI +1.2/+22.8,P=0.030)。
  • 病毒学失败双药组2例(1.5%)vs 三药组9例(6.8%),未出现对研究药物的耐药。
  • 临床不良事件发生率两组相似;双药组3-4级高胆红素血症66.9% vs 三药组50.4%(P=0.006),高甘油三酯血症6.8% vs 1.5%(P=0.031),但从未导致治疗中断。
  • 双药组肾功能和腰椎骨密度显著改善;CD4、HIV-DNA水平和神经认知表现在两组相似。

关键数值与推荐

  • 非劣效界值为-12%。
  • 96周无治疗失败:双药组103/133(77.4%)vs 三药组87/133(65.4%),差异+12.0%(95%CI +1.2/+22.8,P=0.030)。
  • 3-4级高胆红素血症:双药组66.9% vs 三药组50.4%(P=0.006);高甘油三酯血症:双药组6.8% vs 三药组1.5%(P=0.031)。

临床怎么用

  • 作者认为,在病毒学抑制患者中换用阿扎那韦/利托那韦+拉米夫定优于继续阿扎那韦/利托那韦+2NRTI,并持续改善肾功能和骨密度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ritonavir + lamivudine versus continuing a standard regimen with atazanavir/ritonavir + 2NRTI in virologically suppressed patients. METHODS: ATLAS-M is a 96 week open-label, randomized, non-inferiority (margin -12%) trial enrolling HIV-infected adults on atazanavir/ritonavir + 2NRTI, with stable HIV-RNA <50 copies/mL and CD4 counts >200 cells/mm3. At baseline, patients were randomized 1:1 to switch to atazanavir/ritonavir + lamivudine or to continue the previous regimen. Here, we report the 96 week efficacy and safety data. The study was registered with ClinicalTrials.gov, number NCT01599364. RESULTS: Overall, 266 subjects were enrolled (133 in each arm). At 96 weeks, in the ITT population, patients free of treatment failure totalled 103 (77.4%) with atazanavir/ritonavir + lamivudine and 87 (65.4%) with triple therapy (difference +12.0%, 95% CI +1.2/+22.8, P = 0.030), demonstrating the superiority of dual therapy. Two (1.5%) and 9 (6.8%) virological failures occurred in the dual-therapy arm and the triple-therapy arm, respectively, without development of resistance to any study drug. Clinical adverse events occurred at similar rates in both arms. A higher frequency of grade 3-4 hyperbilirubinemia (66.9% versus 50.4%, P = 0.006) and hypertriglyceridaemia (6.8% versus 1.5%, P = 0.031) occurred with dual therapy, although this never led to treatment discontinuation. A significant improvement in renal function and lumbar spine bone mineral density occurred in the dual-therapy arm. The evolution of CD4, HIV-DNA levels and neurocognitive performance was similar in both arms. CONCLUSIONS: In this randomized study, a treatment switch to atazanavir/ritonavir + lamivudine was superior over the continuation of atazanavir/ritonavir + 2NRTI in virologically suppressed patients, with a sustained benefit in terms of improved renal function and bone mineral density.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Fabbiani M, Gagliardini R, Ciccarelli N, et al. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018. PMID: 29668978. doi:10.1093/jac/dky123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。